CJC-1295 vs Tesamorelin — two GHRH analogues, one of them a drug
CJC-1295 and Tesamorelin are both analogues of growth-hormone-releasing hormone acting at the GHRH receptor. Each carries a structural modification intended to resist the rapid degradation that limits the native hormone, but they were modified differently and for different programmes. Tesamorelin is an FDA-approved prescription drug for a specific indication; CJC-1295 is not.
Native GHRH degrades quickly. Essentially every analogue in this space exists to address that, and the differences between them are differences in how.
Same target, different modifications
| CJC-1295 (no DAC) | Tesamorelin | |
|---|---|---|
| Receptor | GHRH receptor | GHRH receptor |
| Basis | Modified GRF(1-29) | Stabilised GHRH analogue |
| Regulatory status | Not approved | FDA-approved, one indication |
| Merchant listing | Permitted for research listing | Refused as an approved pharmaceutical |
The DAC distinction is not cosmetic
CJC-1295 exists in two forms, with and without a drug affinity complex. They are different molecules with different circulation profiles, and conflating them is one of the more common errors in this category — including on vendor sites that list a single "CJC-1295" with no qualifier at all.
What to verify instead of debating potency
- Which form is being sold, stated explicitly on the product page.
- Which laboratory ran the analysis, named on the certificate.
- Whether a chromatogram is attached, not merely a purity percentage.
- Whether the lot on the certificate matches the lot on the vial.
The compounds discussed here
Go deeper
Frequently asked questions
- Are CJC-1295 and Tesamorelin the same class?
- Yes, both are GHRH analogues acting at the GHRH receptor. Where they differ is in the modification each carries and, more consequentially, in whether they hold regulatory approval.
- What does 'no DAC' mean on CJC-1295?
- DAC refers to a drug affinity complex, an added element intended to extend circulation time. The no-DAC form omits it. The two forms are different molecules and should never be treated as one product with a formatting variation — which is why the parenthetical stays in the product name.
- Why does the approval difference matter to a buyer?
- It governs where each compound can be listed and advertised. Approved pharmaceuticals are refused by Google Merchant Center and restricted by most payment processors. That constrains commerce around the compound without saying anything about the material itself.
References
Primary literature for the compounds above. Links open the record on PubMed.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Falutz J, et al. J Acquir Immune Defic Syndr. 2010. PMID 20101189 → · summary
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV Falutz J, et al. N Engl J Med. 2007. PMID 18057338 → · summary
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Ionescu M, et al. J Clin Endocrinol Metab. 2006. PMID 17018654 → · summary
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683 → · summary